Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma

Si L.Zhang X.Shin S.J.Fan Y.CHIA-CHI LINKim T.M.Dechaphunkul A.Maneechavakajorn J.Wong C.S.Ilankumaran P.Lee D.-Y.Gasal E.Li H.Guo J.2022-09-152022-09-1520200959-8049https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086124129&doi=10.1016%2fj.ejca.2020.04.044&partnerID=40&md5=e6981f83f9f2cf57a9229a7b9280885ehttps://scholars.lib.ntu.edu.tw/handle/123456789/620231Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomajournal article10.1016/j.ejca.2020.04.044325342422-s2.0-85086124129